139 related articles for article (PubMed ID: 35628616)
1. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized
Hihara F; Matsumoto H; Yoshimoto M; Masuko T; Endo Y; Igarashi C; Tachibana T; Shinada M; Zhang MR; Kurosawa G; Sugyo A; Tsuji AB; Higashi T; Kurihara H; Ueno M; Yoshii Y
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628616
[TBL] [Abstract][Full Text] [Related]
2.
Yoshii Y; Matsumoto H; Yoshimoto M; Oe Y; Zhang MR; Nagatsu K; Sugyo A; Tsuji AB; Higashi T
J Nucl Med; 2019 Oct; 60(10):1437-1443. PubMed ID: 30850497
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with
Tachibana T; Yoshii Y; Matsumoto H; Zhang MR; Nagatsu K; Hihara F; Igarashi C; Sugyo A; Tsuji AB; Higashi T
J Cancer Res Ther; 2022; 18(4):907-914. PubMed ID: 36149139
[TBL] [Abstract][Full Text] [Related]
4. Integrated treatment using intraperitoneal radioimmunotherapy and positron emission tomography-guided surgery with
Yoshii Y; Yoshimoto M; Matsumoto H; Tashima H; Iwao Y; Takuwa H; Yoshida E; Wakizaka H; Yamaya T; Zhang MR; Sugyo A; Hanadate S; Tsuji AB; Higashi T
Oncotarget; 2018 Jun; 9(48):28935-28950. PubMed ID: 29989003
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
[TBL] [Abstract][Full Text] [Related]
6. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
7. Copper-67 radioimmunotherapy and growth inhibition by anti-L1-cell adhesion molecule monoclonal antibodies in a therapy model of ovarian cancer metastasis.
Knogler K; Grünberg J; Zimmermann K; Cohrs S; Honer M; Ametamey S; Altevogt P; Fogel M; Schubiger PA; Novak-Hofer I
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):603-11. PubMed ID: 17255283
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal radioimmunotherapy to treat the early phase of peritoneal dissemination of human colon cancer cells in a murine model.
Kinuya S; Yokoyama K; Fukuoka M; Hiramatsu T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
Nucl Med Commun; 2007 Feb; 28(2):129-33. PubMed ID: 17198354
[TBL] [Abstract][Full Text] [Related]
9. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer.
Guo Y; Parry JJ; Laforest R; Rogers BE; Anderson CJ
J Nucl Med; 2013 Sep; 54(9):1621-9. PubMed ID: 23873478
[TBL] [Abstract][Full Text] [Related]
10. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer.
Schoffelen R; van der Graaf WT; Sharkey RM; Franssen GM; McBride WJ; Chang CH; Bos DL; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Dec; 53(12):1926-32. PubMed ID: 23081995
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A"-C595.
Qu CF; Songl YJ; Rizvi SM; Li Y; Smith R; Perkins AC; Morgenstern A; Brechbiel M; Allen BJ
Cancer Biol Ther; 2005 Aug; 4(8):848-53. PubMed ID: 16082185
[TBL] [Abstract][Full Text] [Related]
12. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer.
Kuwada K; Kagawa S; Yoshida R; Sakamoto S; Ito A; Watanabe M; Ieda T; Kuroda S; Kikuchi S; Tazawa H; Fujiwara T
J Exp Clin Cancer Res; 2018 Dec; 37(1):307. PubMed ID: 30537992
[TBL] [Abstract][Full Text] [Related]
13. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
14. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
15.
Kasten BB; Gangrade A; Kim H; Fan J; Ferrone S; Ferrone CR; Zinn KR; Buchsbaum DJ
Nucl Med Biol; 2018 Mar; 58():67-73. PubMed ID: 29413459
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer.
Jiao R; Allen KJH; Malo ME; Helal M; Jiang Z; Smart K; Buhl SV; Rickles D; Bryan RA; Dadachova E
Cancer Med; 2019 Sep; 8(11):5289-5300. PubMed ID: 31309741
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation of ⁸⁹Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
Nucl Med Commun; 2015 Mar; 36(3):286-94. PubMed ID: 25460304
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy.
Bryan JN; Jia F; Mohsin H; Sivaguru G; Anderson CJ; Miller WH; Henry CJ; Lewis MR
Cancer Biol Ther; 2011 Jun; 11(12):1001-7. PubMed ID: 21464612
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment of pancreatic cancer xenograft with
Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T; Higashi T
World J Gastroenterol; 2017 Nov; 23(42):7551-7562. PubMed ID: 29204055
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-α6β4 integrin antibody.
Aung W; Tsuji AB; Sudo H; Sugyo A; Ukai Y; Kouda K; Kurosawa Y; Furukawa T; Saga T
Oncotarget; 2016 Jun; 7(25):38835-38844. PubMed ID: 27246980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]